DOCSLIB.ORG

Annex VII-A Substances and Related Substance Groups; Procurement Procedure Ref. EMA/2014/48/PH

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annex VII-A Substances and Related Substance Groups; Procurement Procedure Ref. EMA/2014/48/PH Technical Specifications for open invitation to tender: Procurement procedure ref. EMA/2014/48/PH Annex VII-A Substances and related substance groups ID Substance Group Substances 1 PARACETAMOL ACETYLCYSTEINE, PARACETAMOL 1 PARACETAMOL ASCORBIC ACID, DIMETOFRINE, ISOPROPAMIDE IODIDE, PARACETAMOL, ANHYDROUS CAFFEINE, CHLORPHENIRAMINE MALEATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, ACETYLSALICYLIC ACID 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, CAFFEINE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, CHLORPHENIRAMINE MALEATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, PHENYLEPHRINE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, PROPYPHENAZONE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, SODIUM BICARBONATE, POTASSIUM BICARBONATE, SODIUM CARBONATE ANHYDROUS, ANHYDROUS CITRIC ACID 1 PARACETAMOL BROMPHENIRAMINE MALEATE, ASCORBIC ACID, PARACETAMOL, CAFFEINE 1 PARACETAMOL BROMPHENIRAMINE MALEATE, PARACETAMOL, CAFFEINE 1 PARACETAMOL BUCLIZINE HYDROCHLORIDE, DOCUSATE SODIUM, PARACETAMOL, CODEINE PHOSPHATE 1 PARACETAMOL BUCLIZINE HYDROCHLORIDE, PARACETAMOL, CODEINE PHOSPHATE 1 PARACETAMOL CARBASALATE CALCIUM, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, ASCORBIC ACID, ISOPROPAMIDE IODIDE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, ASCORBIC ACID, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, ASCORBIC ACID, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, ASCORBIC ACID, PARACETAMOL, CAFFEINE CITRATE 1 PARACETAMOL CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, ISOPROPAMIDE IODIDE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, SALICYLAMIDE, ANHYDROUS CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, SODIUM ASCORBATE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL PH. EUR. 1 PARACETAMOL CHLORPHENAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL, PHENYLEPHRINE 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL, PSEUDOEPHEDRINE 1 PARACETAMOL CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR. 1 PARACETAMOL CODEINE PHOSPHATE HEMIHYDRATE, PARACETAMOL DC 1 PARACETAMOL CODEINE PHOSPHATE SESQUIHYDRATE, PARACETAMOL 1 PARACETAMOL CODEINE PHOSPHATE SESQUIHYDRATE, PARACETAMOL, PROPYPHENAZONE, CAFFEINE 1 PARACETAMOL CYANOCOBALAMIN, PARACETAMOL, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE 1 PARACETAMOL DEXCHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXCHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PARACETAMOL, EPHEDRINE SULFATE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL, DOXYLAMINE HYDROGEN SUCCINATE, EPHEDRINE SULFATE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL, PHENYLPROPANOLAMINE HYDROCHLORIDE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PROMETHAZINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, ASCORBIC ACID, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN, PARACETAMOL Page 1 of 69 ID Substance Group Substances 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL, CHLORPHENIRAMINE MALEATE 1 PARACETAMOL DEXTROMETHORPHAN, PARACETAMOL, PSEUDOEPHEDRINE 1 PARACETAMOL DEXTROPROPOXYPHENE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROPROPOXYPHENE, PARACETAMOL, CAFFEINE 1 PARACETAMOL DICLOFENAC SODIUM, PARACETAMOL 1 PARACETAMOL DIHYDROCODEINE TARTRATE, PARACETAMOL 1 PARACETAMOL DIHYDROCODEINE TARTRATE, PARACETAMOL, GELATINE 1 PARACETAMOL DIMENHYDRINATE, PARACETAMOL, CAFFEINE 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE, EPHEDRINE HYDROCHLORIDE 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, CAFFEINE, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR. 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL, PHOLCODINE 1 PARACETAMOL DOXYLAMINE SUCCINATE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE 1 PARACETAMOL DOXYLAMINE SUCCINATE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL DROTAVERINE HYDROCHLORIDE, PARACETAMOL, CODEINE PHOSPHATE 1 PARACETAMOL DROTAVERINE HYDROCHLORIDE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL ERGOTAMINE TARTRATE, PARACETAMOL, BELLADONNA ALKALOIDS, CAFFEINE 1 PARACETAMOL GUAIFENESIN, PARACETAMOL 1 PARACETAMOL GUAIFENESIN, PARACETAMOL, CAFFEINE 1 PARACETAMOL IBUPROFEN, PARACETAMOL 1 PARACETAMOL ISOMETHEPTENE MUCATE, PARACETAMOL 1 PARACETAMOL LIDOCAINE HCL, PARACETAMOL 1 PARACETAMOL METAMIZOLE SODIUM, PARACETAMOL, PHENOBARBITAL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL METAMIZOLE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE 1 PARACETAMOL METHOCARBAMOL, PARACETAMOL 1 PARACETAMOL METOCLOPRAMIDE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL METOCLOPRAMIDE, PARACETAMOL 1 PARACETAMOL ORPHENADRINE CITRATE, PARACETAMOL 1 PARACETAMOL OXYCODONE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL PARACETAMOL 1 PARACETAMOL PARACETAMOL DC 1 PARACETAMOL PARACETAMOL PH. EUR. 1 PARACETAMOL PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al
    US 201401.00249A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears et al. (43) Pub. Date: Apr. 10, 2014 (54) THERAPEUTIC TREATMENT A63/37 (2006.01) A613 L/45 (2006.01) (71) Applicants: Douglas Sears, Oak Park, CA (US); A613 L/4458 (2006.01) Michael Reilly, Oak Park, CA (US) (52) U.S. Cl. CPC ............... A61K 45/06 (2013.01); A61 K3I/451 (72) Inventors: Douglas Sears, Oak Park, CA (US); (2013.01): A613 L/4458 (2013.01); A61 K Michael Reilly, Oak Park, CA (US) 3 1/137 (2013.01); A61 K31/165 (2013.01) USPC .......................................................... S14/325 (21) Appl. No.: 14/046,528 (57) ABSTRACT (22) Filed: Oct. 4, 2013 This invention discloses a treatment for a patient receiving O O medication to treat an attention deficit disorder Such as Related U.S. Application Data ADHD wherein the treatment results in a loss of appetite and (60) Provisional application No. 61/744,948, filed on Oct. impairment of the patient's attentiveness. The treatment com 9, 2012, now abandoned. bines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases Publication Classification the caloric intake of a patient, which can increase the patients attentiveness. The combination treatment can be given for an (51) Int. Cl. indefinite, including, without limitation, life-long, to allow a A6 IK 45/06 (2006.01) patient to maintain normal caloric intake during treatment for A6 IK3I/65 (2006.01) an attention deficit disorder. 8aasaias: Patent Application Publication Apr. 10, 2014 Sheet 1 of 22 US 2014/010O249 A1 Figure i: improvement in Atiention with increased Caiotic intake 8aakast Patent Application Publication Apr.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Chlorphenamine Maleate)
    Package leaflet: Information for the patient Chlorphenamine 10 mg/ml Solution for Injection (Chlorphenamine Maleate) Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor or nurse. − If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Chlorphenamine is and what it is used for 2. What you need to know before Chlorphenamine is given 3. How Chlorphenamine is given 4. Possible side effects 5. How to store Chlorphenamine 6. Contents of the pack and other information 1. What Chlorphenamine is and what it is used for Chlorphenamine 10 mg/ml Solution for Injection contains the active ingredient chlorphenamine maleate which is an antihistamine. Chlorphenamine is indicated in adults and children (aged 1 month to 18 years) for the treatment of acute allergic reactions. These medicines inhibit the release of histamine into the body that occurs during an allergic reaction. This product relieves some of the main symptoms of a severe allergic reaction. 2. What you need to know before Chlorphenamine is given You MUST NOT be given Chlorphenamine: if you are allergic to chlorphenamine maleate or any of the other ingredients of this medicine (listed in section 6) if you have had monoamine oxidase inhibitor (MAOI) antidepressive treatment within the past 14 days. Warnings and precautions Talk to your doctor or nurse before you are given this medicine if you: are being treated for an overactive thyroid or enlarged prostate gland have epilepsy, raised blood pressure within the eye or glaucoma, very high blood pressure, heart, liver, asthma or other chest diseases.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • Oregon Department of Human Services HEALTH EFFECTS INFORMATION
    Oregon Department of Human Services Office of Environmental Public Health (503) 731-4030 Emergency 800 NE Oregon Street #604 (971) 673-0405 Portland, OR 97232-2162 (971) 673-0457 FAX (971) 673-0372 TTY-Nonvoice TECHNICAL BULLETIN HEALTH EFFECTS INFORMATION Prepared by: Department of Human Services ENVIRONMENTAL TOXICOLOGY SECTION Office of Environmental Public Health OCTOBER, 1998 CALCIUM CARBONATE "lime, limewater” For More Information Contact: Environmental Toxicology Section (971) 673-0440 Drinking Water Section (971) 673-0405 Technical Bulletin - Health Effects Information CALCIUM CARBONATE, "lime, limewater@ Page 2 SYNONYMS: Lime, ground limestone, dolomite, sugar lime, oyster shell, coral shell, marble dust, calcite, whiting, marl dust, putty dust CHEMICAL AND PHYSICAL PROPERTIES: - Molecular Formula: CaCO3 - White solid, crystals or powder, may draw moisture from the air and become damp on exposure - Odorless, chalky, flat, sweetish flavor (Do not confuse with "anhydrous lime" which is a special form of calcium hydroxide, an extremely caustic, dangerous product. Direct contact with it is immediately injurious to skin, eyes, intestinal tract and respiratory system.) WHERE DOES CALCIUM CARBONATE COME FROM? Calcium carbonate can be mined from the earth in solid form or it may be extracted from seawater or other brines by industrial processes. Natural shells, bones and chalk are composed predominantly of calcium carbonate. WHAT ARE THE PRINCIPLE USES OF CALCIUM CARBONATE? Calcium carbonate is an important ingredient of many household products. It is used as a whitening agent in paints, soaps, art products, paper, polishes, putty products and cement. It is used as a filler and whitener in many cosmetic products including mouth washes, creams, pastes, powders and lotions.
    [Show full text]
  • Ocean Acidification and Oceanic Carbon Cycling 13
    Ocean Acidification and Oceanic Carbon Cycling 13 Dieter A. Wolf-Gladrow and Bjo¨rn Rost Contents Atmospheric CO2 ............................................................................... 104 Air-Sea CO2 Exchange and Ocean Carbonate Chemistry ..................................... 104 Rate of Surface Ocean Acidification and Regional Differences .. ........................... 104 The Physical Carbon Pump and Climate Change .............................................. 105 Impact of Ocean Acidification on Marine Organisms and Ecosystems ....................... 106 The Biological Carbon Pump and Climate Change ............................................ 107 Take-Home Message ............................................................................ 108 References ....................................................................................... 109 Abstract The concentration of atmospheric CO2 is increasing due to emissions from burning of fossil fuels and changes in land use. Part of this “anthropogenic CO2” invades the oceans causing a decrease of seawater pH; this process is called “ocean acidification.” The lowered pH, but also the concomitant changes in other properties of the carbonate system, affects marine life and the cycling of carbon in the ocean. Keywords Anthropogenic CO2 • Seawater acidity • Saturation state • Climate change • Physical carbon pump • Global warming • Biological carbon pumps • Phyto- plankton • Primary production • Calcification D.A. Wolf-Gladrow (*) • B. Rost Alfred Wegener Institute, Helmholtz Centre
    [Show full text]
  • Contact Allergy to Aluminium Siemund, Ingrid
    Contact allergy to aluminium Siemund, Ingrid 2017 Document Version: Publisher's PDF, also known as Version of record Link to publication Citation for published version (APA): Siemund, I. (2017). Contact allergy to aluminium. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 INGRID SIEMUND INGRID Contact allergy to aluminium Contact allergy to aluminium INGRID SIEMUND | DEPARTMENT OF OCCUPATIONAL AND ENVIRONMENTAL DERMATOLOGY | SKÅNE UNIVERSITY HOSPITAL, LUND UNIVERSITY 9 Department of Occupational and 789176 Environmental Dermatology Lund University, Faculty of Medicine 2017:113 Doctoral Dissertation Series 2017:113 194959 ISBN 978-91-7619-495-9 ISSN 1652-8220 Contact allergy to aluminium 1 2 Contact allergy to aluminium Ingrid Siemund DOCTORAL DISSERTATION by due permission of the Faculty of Medicine, Lund University, Sweden.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Butenafine Hydrochloride/Climbazole 529 to Be Reduced in Patients with Hepatic Impairment (See Profile Solution in Water Has a Ph of 8.0 to 9.0
    Butenafine Hydrochloride/Climbazole 529 to be reduced in patients with hepatic impairment (see Profile solution in water has a pH of 8.0 to 9.0. Protect from light. below). Chlormidazole hydrochloride is an imidazole antifungal used USP 31 (Ciclopirox Olamine). A white to slightly yellowish- topically as the hydrochloride in the treatment of fungal infec- white, crystalline powder. Slightly soluble in water; very soluble ◊ Reviews. tions of the skin. in alcohol and in dichloromethane; practically insoluble in cy- 1. Letscher-Bru V, Herbrecht R. Caspofungin: the first representa- For a discussion of the caution needed when using azole antifun- clohexane. pH of a 1% solution in water is between 8.0 and 9.0. tive of a new antifungal class. J Antimicrob Chemother 2003; 51: gals during pregnancy, see under Pregnancy in Precautions of Store in airtight containers at a temperature of 5° to 25°. Protect 513–21. Fluconazole, p.532. from light. 2. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445–57. Preparations Adverse Effects 3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: Proprietary Preparations (details are given in Part 3) Irritation and pruritus have been reported after topical applica- 1142–51. Pol.: Unifungicid. tion of ciclopirox. 4. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049–68. Multi-ingredient: Austria: Myco-Synalar; Pol.: Polfungicid; Switz.: Antimicrobial Action 5. Morris MI, Villmann M. Echinocandins in the management of Myco-Synalar†. Ciclopirox has a wide spectrum of antifungal activity. It inhibits invasive fungal infections, part 1.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct
    USOO525371 1A United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct. 19, 1993 54) PROCESS FOR DECOMPOSING 2,268,215 12/1941 Kerr ...................................... 127/33 POLYSACCHARDES IN ALKALINE 3,167,510 /1965 Alter ..... sa as A8 a X8 a P. 252/8.551 3,655,644 4/1972 Durand ........................... 106/21 X AQUEOUS SYSTEMS 3,935,187 1/1976 Speakman ........................... 536/102 75 Inventor: Thomas C. Mondshine, Houston, 4,202,795 5/1980 Burnham et al. ............... 166/308 X Tex. 4,552,668 11/1985 Brown et al. ................... 166/300X Lachenal et al. ..................... 162/25 Assignee: Texas United Chemical Corp., 4,787,959 11/1988 (73) Primary Examiner-George A. Suchfield Houston, Tex. Attorney, Agent, or Firm-Roy F. House 21 Appl. No.: 844,167 57 ABSTRACT 22 Filed: Mar. 2, 1992 Alkaline earth metal or transition metal peroxides are (51) int. Cli.............................................. E21B 43/26 used as a delayed breaker in alkaline aqueous fluids 52) U.S. C. .................................... 166/300; 166/308; containing a water soluble hydrophilic polysaccharide 252/8.551; 252/326 polymer hydrated therein. The peroxide is activated by (58) Field of Search ............................... 166/300, 308; increasing the temperature of the fluid. The invention is 252/8.551, 326,358; 536/41, 80, 88 particularly useful for the delayed break of hydraulic 56) References Cited fracturing fluids containing hydroxypropyl guar poly c. U.S. PATENT DOCUMENTS i,953,398 4/1934 Eskew ................................... 536/41 10 Claims, No Drawings 5,253,711 1. 2 G. W. Hawkins, and H. D. Brannon, Feb.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]